Protein Alternatives receives the Innovative SME Seal

April 9th, 2021. PROALT has received the Innovative SME Seal, valid until April 2024. Innovation is one of the key factors for the economic and social development of any country. Through the Innovative SME Seal, the Ministry of Science and Innovation recognizes companies that carry out activities in the field of research, technological development and [...]

2021-05-04T11:07:52+00:009 April 2021|Tags: , , |

ProAlt’s MetasCure project selected in the R&D and innovation programme of Madrid Region

January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]

2021-05-04T11:08:46+00:0014 January 2021|Tags: , , , |

Protein Alternatives announces the opening of new office in Boston

December 1st, 2020 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of diagnostic and therapeutic products in oncology and research services provider, announces today the opening of its new office in Boston at the Cambridge Innovation Center (CIC). United States is one of the priority markets for the organization and [...]

2020-12-01T11:29:02+00:001 December 2020|Tags: , |

METASTCURE colon cancer therapeutic project receives the Seal of Excellence recognition from the EU H2020 Programme

November 25th, 2020 PROALT’s project proposal named ‘METASTCURE – Anti cadherin-RGD monoclonal antibody PA-0661 for the treatment of metastatic colorectal cancer’ has received the Seal of Excellence recognition from the Enhanced European Innovation Council (EIC) pilot in EU. The EIC Accelerator programme is part of the Enhanced European Innovation Council pilot and provides grant and blended [...]

2020-11-27T14:44:08+00:0025 November 2020|Tags: , , , , |

PROFILUX Lung Cancer diagnostic project receives funding from the EU Eurostars Programme and CDTI

April 1st, 2020 The project proposal named ‘PROFILUX – Saliva- and blood-based lung cancer detection based on tumour auto-antibody profiling’ has been selected to receive funding from the EU Eurostars Programme. The company received the official communication in January and the project started on April. The international research consortium where PROALT participates is leaded by [...]

2020-11-27T14:03:08+00:001 April 2020|Tags: , , , , |

PROALT, nominated for the Innovation Award, presents ColoDetect in MEDICA

Photo: Dr. Juan I. Imbaud during its presentation. 14th, November 2017 PROALT was nominated for the Innovation Award and presented its colorectal cancer diagnostic and therapeutic projects at the eHealth Venture Summit 2017 in November 14th. The competition took place as part of MEDICA HEALTH FORUM in Düsseldorf (Germany) from 13-16 November. The eHealth Venture [...]

2020-05-05T15:33:34+00:0014 November 2017|Tags: , , |

PROALT has launched ColoDetect website to disseminate project results

1st, April 2016 ColoDetect project announces the launch of its website. ColoDetect is a project funded by the European Union through the H2020 SME Instrument Phase 2 and developed by Protein Alternatives (PROALT). The project started in October 2015 and will run for three years. Its objective is the development and commercialization of a blood-based [...]

2020-05-06T07:48:24+00:001 April 2016|Tags: , , |

PROALT receives H2020-SME Instrument funding to develop ColoDetect project

October 1st, 2015 COLODETECT, a proposal submitted by the Spanish biotechnology company PROALT, has been selected to receive EU funding from H2020 SME Instrument. In total, the Commission received 580 project proposals from European SMEs by the first cut-off date of the so-called Horizon 2020’s SME Instrument Phase 2. PROALT is the only Spanish company [...]

2020-05-05T15:36:39+00:001 October 2015|Tags: , , , |

ColoDetect project: featured news in ‘El Mundo’, one of the main national newspapers

May 6th, 2015 The 'Innovators' supplement of the 'El Mundo' newspaper, one of the most widely distributed journals in Spain, has interviewed Dr Juan Ignacio Imbaud, R&D Director of the biotech company Protein Alternatives (Madrid, Spain). The reason was the recent approval of the project named COLODETECT, which was presented by the company to the [...]

2020-05-05T15:37:22+00:005 June 2015|Tags: , , |

ColoDetect project: selected to receive funding from the EU Horizon 2020 Programme

 January 10th, 2015 Protein Alternatives' project proposal named 'ColoDetect - Development of a novel blood-based diagnostic test for colorectal cancer' has been selected to receive funding from the EU Framework Programme Horizon 2020 SME Instrument. The official communication was received by the company in December and the firm is negotiating the grant conditions at the [...]

2020-05-05T15:37:50+00:0010 January 2015|Tags: , , , |
Go to Top